ACE2 enhance viral infection or viral infection aggravate the underlying diseases

Shaolei Teng a,⇑, Qiyi Tang b,⇑

a Department of Biology, Howard University, 415 College St. NW, Washington, DC 20059 USA
b Howard University College of Medicine, 520 W Street NW, Washington, DC 20059 USA

Abstract

ACE2 plays a critical role in SARS-CoV-2 infection to cause COVID-19 and SARS-CoV-2 spike protein binds to ACE2 and probably functionally inhibits ACE2 to aggravate the underlying diseases of COVID-19. The important factors that affect the severity and fatality of COVID-19 include patients' underlying diseases and ages. Therefore, particular care to the patients with underlying diseases is needed during the treatment of COVID-19 patients.

© 2020 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Overview

The order Nidovirales includes four families: Coronaviridae, Arteriviridae, Roniviridae, and Metoniviridae with positive-sense, single-stranded RNA genomes that may infect animals and humans [1–3]. The family Coronaviridae is divide into four main subgroups (or genera): α, β, γ, and δ. Alpha and β genus coronaviruses infect mammals while γ and δ viruses infect primarily birds. So far, only seven coronavirus members from the α and β subfamilies are found to infect humans. They are the α-coronaviruses HCoV-229E and HCoV-OC43, and the β-coronaviruses SARS-CoV.
cases and 774 deaths (https://www.who.int/csr/sars/country/)
of 2002. It lasted for almost a year in the south of China and Viet-
demic originated from Guangdong province, China in November
major outbreaks of beta-coronavirus infection have occurred,
comorbidities.
named COVID-19. Here, we attempt to analyze the available data
CoV-2) has affected almost all countries, resulting in the disease
html). The current (third) pandemic of beta-coronavirus (SARS-
epidemic-diseases/mers-cov/mers-situation-update-january-2020.
[MERS-CoV] that is more reliable than those from the mass media. The first
dated almost a year in the south of China and Viet-
involved more than 30 countries, and ended up with 8096
and 774 deaths (https://www.who.int/csr/sars/country/
table2004_04_21/en/). The patients appeared to have severe acute
respiratory syndrome (SARS). This was also called SARS-1 and the
virus was named SARS-CoV-1. The second beta-coronavirus pan-
demic occurred in Middle Eastern countries in 2012 and was hence
named Middle East respiratory syndrome coronavirus (MERS-CoV)
[10]. The infection was transmitted to 25 countries and resulted in
1360 cases and 527 deaths (http://www.enhvo.who.int/pandemic-
edemic-diseases/mers-cov/mers-situation-update-january-2020.
.html). The current (third) pandemic of beta-coronavirus (SARS-
CoV-2) has affected almost all countries, resulting in the disease
named COVID-19. Here, we attempt to analyze the available data
from publications or from official WHO and USA CDC resources and
derstand the associations between COVID-19 and its comorbidities.

2. SARS-CoV-2, origination of the COVID-19, and spreading.

Like other coronaviruses, SARS-CoV-2 is a single stranded positive
RNA virus with 29,811 nucleotides that encodes 12 putative open
reading frames responsible for more than 26 proteins through
ribosomal frameshifting and host proteasomal processing [11,12].
The first step of viral infection is attachment, which depends on
the interaction of the viral surface with cellular receptors. The
SARS-CoV-2 spike protein (S) is cleaved by the human furin
enzyme to generate two subunits, S1 and S2, that are arranged to
extrude outward from the viral particle. Both S1 and S2 play crucial
roles for viral entry [3]. The S1 subunit binds to the host receptor
angiotensin converting enzyme 2 (ACE2) (Table 1). While its
binding to the membrane-bound ACE2 promotes viral attachment
to infected cells, the soluble ACE2 might prevent viral infection by
binding to S1 [13]. The S2 subunit, after S1’s interaction with ACE2,
promotes viral fusion with the host cell membrane via interaction
with transmembrane protease, serine 2 (TMPRSS2) and enables
viral entry [3]. Interestingly, TMPRSS2 has the proteolytic effect
on ACE2, which augments the entry of SARS-CoV-1 and probably
CoV-2 [14–16]. After entry, viral particle is endocytosed to the
endosome and uncoated in a pH-related manner. Viral RNA is
released to the host endoplasmic reticulum (ER). Not only do viral
protein translation and RNA transcription happen in the ER, but
also viral polyprotein processing: viral subgenomic RNAs and stem
looped RNAs are formed in the ER. Newly generated viral particles
are assembled in the Golgi body for exit out of cells. The viral mem-
brane protein (M), important for maintaining viral structure and
the viral envelop protein (E) together play roles in viral assembly
and release. Although the basis of viral replication is outlined as
above, many aspects are still not understood, especially for the
polyprotein processing, ribosomal frameshifting and formation of
subgenomic RNAs. We will specifically discuss the interaction of
SARS-CoV-2 with ACE2 in this minireview.

Viral origin has been a standing hot topic of SARS-CoV-2 for a
variety of reasons. Here we trace the early published information
that are more reliable than those from the mass media. The first
two confirmed COVID-19 cases occurred in Wuhan, China on
December 8th and 10th of 2019. The patients never went to the
Huanan seafood market that was disputed to be the origin of
SARS-CoV-2. In the next 10 days (December 13 to 23), more
cases were found. Among the total 25 cases found during these
days, 15 patients went to the seafood market; therefore, the
seafood market was argued to be the origin of SARS-CoV-2. An epi-
demiological analysis of the first 425 cases in Wuhan found that
most subsequently obtained infections were not originated from
the Huanan seafood market [17]. It is now more or less denied
by epidemiologists that the Huanan seafood market could have
any link with the virus [18,19]. However, the seafood market origin
of SARS-CoV-2 became mythologized. The outbreak in Wuhan
caused the viral spreading to other provinces in China by late Jan-
uary while it was later transmitted to other countries: first to Thai-
land, then USA, France, Germany and Italy. Sothern Korea and Italy
are among the first countries with outbreaks in February [17,20]. It
quickly became a pandemic and affects more than 200 countries
now with more than 3 million cases and over 200,000 deaths
globally.

A previously isolated bat coronavirus (BatCoV RaTG13) has been
identified that shares more than 96% homology in nucleotide
sequences and more than 97% homology in amino acid sequences
with SARS-CoV-2 [21]. This study implied that the SARS-CoV-2
might have originated from bats. However, bats are not a common
resident animal in the city of Wuhan. Therefore, an intermediate
host for SARS-CoV-2 is believed to exist assuming it is a zoonotic
virus. One study found that a coronavirus isolated from the pan-
golin is 91.02% and 90.55% identical in nucleotide sequences to
SARS-CoV-2 and BatCoV RaTG13, respectively [22]. Another study
showed that SARS-CoV-2 is possibly associated with coronaviruses
derived from some wild animals, including Paguma larvata, Para-
doxurus hermaphroditus, in the same branch of the phylogenetic
tree [23]. However, they all are unlikely the intermediate host
because the genome and ORF1a homology show that the virus is
not even close to SARS-CoV-2. Given SARS-CoV-2 is originated from
bat RaTG13, the virus from the intermediate host should be closer
to SARS-CoV-2 than to the RaTG13. Although it is difficult to find it,
the intermediate host is still the interest of virologists [24,25]. Sur-
prisingly, a research group screened the susceptibilities of different
species of animals to SARS-CoV-2 infection and found that cats
and ferrets are very susceptible to SARS-CoV-2. On the contrary,

Table 1
The Receptors for the Human Pathogenic Coronaviruses.

| Subfamily | Name          | Receptor                  |
|-----------|---------------|---------------------------|
| alpha-coronavirus | HCoV-229E | aminopeptidase N (APN) [3,82] |
| alpha-coronavirus | HCoV-OC43  | N-Acetylneuraminic acid (Neu5Ac or NANA) [10,83] |
| beta-coronavirus | SARS-CoV-1  | angiotensin converting enzyme 2 (ACE2) [10,62,84] |
| beta-coronavirus | HCoV-NL63  | angiotensin converting enzyme 2 (ACE2) [10,64] |
| beta-coronavirus | CoV-HKU1   | dipeptidyl peptidase 4 (DPP4) [10,85] |
| beta-coronavirus | MERS-CoV    | dipeptidyl peptidase 4 (DPP4) [10,86] |
| beta-coronavirus | SARS-CoV-2  | angiotensin converting enzyme 2 (ACE2) [21,68] |
3. Underlying diseases of COVID-19 and the Renin-angiotensin system (RAS).

The first recorded COVID-19 case in the USA was in Seattle, Washington on January 19th, 2020 in a patient who traveled back from Wuhan, China. Two days later, cases were reported in Chicago on January 21st, 2020. Another two days later, COVID-19 cases were confirmed in California and Arizona. These early cases all occurred in patients who traveled from China. Due to its highly contagious nature, SARS-CoV-2 has proven catastrophic in both prevalence and fatality in the United States. The most important difference between SARS-CoV-2, SARS-CoV-1 (2002) and MERS-CoV (2009) is that SARS-CoV-2 is highly contagious with a much higher reproductive number (R0) of 5.7 [27] or 3.57 [28] is rapidly spreading to other countries and territories to cause COVID-19. More importantly, epidemic data suggests that the COVID-19 might become a seasonal pandemic at a similar or even a larger scale [29]. Although the final fatality rate is the most accurate and can only be obtained when the pandemic is over, the current data shows that it could be very high in some countries. Interestingly, the fatality by COVID-19 clearly correlates with whether the patients have one or more underlying diseases; the CDC webpage have listed 10 high-risk underlying diseases; the top comorbidities include hypertension and cardiovascular diseases (CVDs) [30–33] and occur at significantly higher rates in the African American and non-white Hispanic groups in the USA [34].

The abovementioned comorbidities of COVID-19, hypertension, DM and CVDs, are closely associated with RAS signaling. Angiotensin I is generated from angiotensinogen by renin after being stimulated by several conditions such as low blood pressure, bleeding and dehydration [35–38]. Angiotensin I is then converted to angiotensin II by angiotensin converting enzyme (ACE) [39,40]. Angiotensin II constricts vasculature to elevate the blood pressure. Therefore, abnormally high levels of angiotensin II cause hypertension and also aggravate DM sequelae and induce CVDs as shown in Fig. 1. Several ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have been clinically used to treat the relevant diseases. Angiotensin II can be subsequently hydrolyzed by ACE2 to generate angiotensin peptides, mainly Angiotensin-1[1–7], also called Ang-(1–7) [41]. Ang-(1–7) is a vasoconstrictor and hence reduces blood pressure (See Fig. 1). ACE II also hydrolyzes the angiotensin I to other peptide angiotensin such as Angiotensin-[1–9] that is another vasoconstrictor [42–44]. Therefore, the RAS signaling is a balanced system that must be maintained for the healthy cardiovascular system with normal blood pressure and normal cardiovascular function.

A theory for explaining how the aforementioned comorbidities significantly increase the fatality of COVID-19 was based on the fact that these patients have a history of taking drugs such as ACEIs, ARBs and ibuprofen [45,46]. These drugs not only inhibit ACE but increase the level of ACE2 as well. The increase of ACE2 might elevate the chances of infection of SARS-CoV-2, which directly relates to the viral infection and fatality. This theory is shown in the left side of Fig. 1 as “ACE2 enhancing viral infection” [45,46]. However, this theory does not explain why the onset of COVID-19 in these patients is so rapid that an emergent rescue is needed and many of them still die. Furthermore, it contradicts the recently published reports that using ARBs and ACEIs improved COVID-19 [47–49]. Some critical reviews analyzed the available evidence and found that it does not support a deleterious effect of RAS blockers in COVID-19 [50–52]. Therefore, it is suggested that there is currently no reason to discontinue RAS blocking ACEIs in stable patients who suffer from the COVID-19 [50].

ACE2 is a cell membrane protein in lungs, arteries, heart, kidney and intestines [53–55]. ACE2 converts angiotensin II to peptide Ang-(1–7) or angiotensin I to peptide Ang-(1–9); both peptides are vasodilators [35,41,56–58]. Therefore, ACE2 physiologically reduces blood pressure and is anti-hypertensive when the angiotensin II is elevated. SARS-CoV-2 spike protein (S) is cleaved by the human furin enzyme to generate S1, which binds to the host receptor, ACE-2. It is possible that the released free spike or the cleaved S1 protein in the blood might bind to cellular membrane ACE2 of heart, artery and alveolar lung cells to block the conversion of Angiotensin II to Ang-(1–7) and/or Angiotensin I to Ang-(1–9), which is consistent with a previous experimental result on SARS-CoV-1 [59]. The interaction with SARS-CoV-2 S protein might exhaust ACE-2 or damage ACE-2 function. Therefore, our hypothesis, as shown in the right side of Fig. 1 as “Viral aggravating existing diseases”, is that comorbidities in COVID-19 patients are aggravated by the infection of SARS-CoV-2 to causes higher fatalities because the viral S protein interacts with ACE2 to inhibit ACE2 function. This hypothesis is also supported by a clinical finding that an imbalance of the AngII-Ang-2 (1–7) axis occurs in human pulmonary artery hypertension (PAH), with reduced ACE2 levels implicated in the pathogenesis of severe PAH [60]. However, an animal study demonstrated that ACE2 level in lung is low and that Prolyloligopeptidase (POP) is the main enzyme responsible for Ang II conversion to Ang-(1–7) in the lungs [61]. Therefore, an alternative mechanism might exist when ACE2 is harvested in COVID-19 patients.

![Fig. 1. Two theories to explain the severity of COVID-19](image-url)
4. ACE2 and spike protein

ACE2 is the receptor of spike proteins of beta-coronaviruses including SARS-CoV-1, HCoV-NL63 and SARS-CoV-2. Li et al. (2003) isolated ACE2 from SARS-CoV Vero E6 cells [62]. They found a high-affinity binding between ACE2 and the S1 domain of SARS-CoV-1 spike protein and showed that anti-ACE2 antibody could inhibit viral replication in Vero E6 cells. They reported the crystal structure of SARS-CoV-1 envelope-anchored spike protein with ACE2 [63]. The receptor-binding domain (RBD) of SARS-CoV-1 spike protein includes a core and a receptor-binding motif (RBM) that specifically recognizes ACE2. The interactions between RBD and ACE2 are critical for the host range and cross-species infections of SARS-CoV-1. A study of receptor analysis showed that human coronavirus NL63 (HCoV-NL63) spike protein uses ACE2 as the receptor for infection of SARS-CoV [64]. Unlike SARS-CoV-1 and SARS-CoV-2, HCoV-NL63 infects mainly children and causes only mild respiratory disease [65]. Both SARS-CoV-1 and SARS-CoV-2 can cause severe acute respiratory syndrome. The amino acid sequence similarities of SARS-CoV-1 and SARS-CoV-2 in the spike protein, RBD, and RBM are 76%, 73% and 50%, respectively [66]. A novel furin cleavage site was identified at the boundary between the S1/S2 subunits of SARS-CoV-2 but not in SARS-CoV-1 and other closely SARS-related CoVs [67]. Recent studies revealed that SARS-CoV-2 uses ACE2 as a receptor for cellular entry [67,68]. SARS-CoV-2 first binds to ACE2 via RBD of its spike protein and then fuses viral and host membranes [67]. The study also showed that SARS-CoV-1 spike polyclonal antibodies block SARS-CoV-2 mediated entry into host cells and cross-neutralizing antibodies may provide protection against SARS-CoV-2 [67].

Structure analyses of SARS-CoV-2 spike protein with ACE2 complex have elucidated that the efficiency of ACE2 usage is the key determinant of SARS-CoV-2 transmissibility [67,69,70]. In the presence of the amino acid transporter B0AT1, the human ACE2 structure can form a dimer of heterodimers via its collectrin-like domain [70]. The peptidase domain of ACE2 can interact with the RBD of SARS-CoV-2 spike protein through polar interactions, and the mode of binding interface is similar to that between SARS-CoV-1 and ACE2 [70]. Walls et al. determined cryo-EM structures of the SARS-CoV-2 spike ectodomain trimer in open and closed conformations [67]. In the closed conformation, the ACE2 binding motifs are buried at the interface between promoters. SARS-CoV-2 spike protein can recognize ACE2 in the open conformation and initiate membrane fusion and viral entry. They also showed that the binding affinity of SARS-CoV-2 and ACE2 is comparable to or higher than those for SARS-CoV-1. Wang et al. reported the crystal structure of SARS-CoV-2 spike RBD with human ACE2 [69]. They identified more contacted residues and larger buried surface areas in SARS-CoV-2/ACE2 than in SARS-CoV-1/ACE2 complex. As shown in Fig. 2, SARS-CoV-2 binds to ACE2 via the RBM of its spike RBD. Key residues in ACE2 can strengthen the binding affinity of SARS-CoV-2/ACE2 complex (Table 2). For example, ACE2 residue S19 can form a strong polar contact with SARS-CoV-2 residue A475, where some monoclonal antibodies could not effectively neutralize the viral mutation A475V in this site [71]. D355 in ACE2 can form hydrogen-bonds with T500 and G502 in SARS-CoV-2. Molecular dynamics study suggested that D355 is involved in a critical hydrogen-bonding network of RBD-ACE2 interaction [72]. ACE2 residue M82 and SARS-CoV-2 residue F486 are involved in hydrophobic interactions at the interface. F486 has been identified as a binding site for neutralizing antibodies [73]. These results explain the efficient transmission of SARS-CoV-2 in humans.

The sequence variants in ACE2 have been found to be related to human complex disorders. Several case-control association studies identified the ACE2 genetic single nucleotide polymorphisms associated with hypertension [74,75]. The coding mutations in key residues of ACE2 may alter the binding affinity of SARS-CoV-2/ACE2 complex and change pathogenicity of ACE2. High-throughput

![Fig. 2. The structure of human ACE2 with SARS-CoV-2 Spike RBD: Human receptor ACE2 (green), SARS-CoV-2 spike receptor-binding domain (RBD, yellow orange) and receptor-binding motif (RBM: brown) were shown as cartoons. ACE2 contacted residues, including S19 (purple), T27 (red), E35 and E27 (magenta), M82 (orange) and D355 (hot pink), were displayed as sticks. The image was generated using PyMOL (http://www.pymol.org) based on PDB ID: 6LZG. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](http://www.pymol.org)
One of the important facts is that the aforementioned comorbidities of hypertension, DM and CVDs are less common in younger people than that in older people. The underlying diseases links to both the case fatality of COVID-19 and the economically disadvantaged groups and/or socially isolated communities. For example, as Dr. Yancy summarized [34], 1) more than 50% of COVID-19 cases and nearly 70% of COVID-19 deaths involve African American individuals, although they make up only 30% of the population in Chicago; 2) 70.5% of deaths have occurred among African American persons, who represent 32.2% of the state’s population in Louisiana; 3) 33% of COVID-19 cases and 40% of deaths have occurred among African American individuals, who represent 14% of the population in Michigan; and 4) New York City is the epicenter of COVID-19 in the USA, African Americans and Hispanics have accounted for 28% and 34% of deaths, respectively (population representation: 22% and 29%, respectively). Dr. Yancy also noted that it is likely that some, if not most, of these differences in disease rates and outcomes will be explained by concomitant comorbidities. However, it is possible that the majority of the disparity has to do with access to healthcare, education about the virus and its symptoms, or other well-documented socioeconomic disparities in US healthcare.

The claims that COVID-19 disproportionately affects the individuals of minority groups and aged people are not only supported by reported data but also by our hypothesis that SARS-CoV-2 infection generates spike protein that interacts with ACE2 to either exhaust ACE2 or inhibit ACE2 function or both so that the comorbidities are aggravated (Fig. 1). The top comorbidities in COVID-19 patients are hypertension, and cardiovascular disease, all of which are directly related to ACE2. Therefore, we suggest that ACE2-SARS-CoV-2 spike interaction is a specific target not only for treatment of the severe diseases but also for prophylactic control of the infection of SARS-CoV-2. The strategies of using the target might be better against the spike protein of SARS-CoV-2 than ACE2 because targeting ACE2 per se might impose a detrimental effect on the patient who has the underlying diseases.

### 5. COVID-19 and health disparities.

Different disparities have been reported in populations with COVID-19 whose deaths are related to older age, male sex, and comorbid diseases [34]. First, it was noted that the deaths caused by COVID-19 clearly associate with age of the patients. This was first reported for the COVID-19 populations in Wuhan, China [76] where the median age of patients who died was 75 (range 48 to 89). Another study estimated the death rate in China was 0.66% and was increasing by age to 6.4% for age 60 and older, and to 13.8% for age of 80 or older [77,78]. A similar situation was confirmed in UK with 80% of COVID-19-related deaths in those aged 65 years and over and in the USA with those in the 65–84 years age group accounting for 25% of cases, 46% of intensive care unit admissions and 46% of deaths [79,80]. The link between death rate and age has been observed in many countries [81].

Many factors could connect age to COVID-19-caused fatalities. One of the important facts is that the aforementioned comorbidities, and also the comorbid diseases which not only interpret high fatalities but also to COVID-19, especially the biological role of ACE2 in the pathogenesis of COVID-19 and certain comorbid diseases.

| dbSNP      | Mutation | Binding Affinity Prediction | Mutation Pathogenicity Prediction | Allele Count in Different Populations |
|-----------|----------|-----------------------------|-----------------------------------|--------------------------------------|
| rs73635825 | S19P     | 2.83 0.086 Increasing       | Probably Damaging                 | 63 0 0 0 0                          |
| rs781255386 | T27A    | 3.498 1.004 Increasing     | Tolerated                          | 0 2 0 0 0                          |
| rs1348114695 | E35K    | 2.693 –0.668 Decreasing   | Tolerated                          | 0 0 2 0 1                          |
| rs146667783 | E37K    | 3.314 –1.226 Decreasing   | Probably Damaging                 | 0.163 2.669 2 0 0 6 0              |
| rs769996587 | M82I    | 3.382 –0.521 Decreasing   | Tolerated                          | 0.016 –0.646 5 0 0 0 0 0            |
| rs961360700 | D355N   | 3.547 –0.901 Decreasing   | Tolerated                          | 0.430 3.005 0 0 0 0 0 2             |

The effects of variants on binding affinity were predicted using mcsM-ppi2 (http://biosig.unimelb.edu.au/mcsM_ppi2/). Mutation pathogenicity predictions were extracted from dbNSFP (https://sites.google.com/site/jpopgen/dbNSFP/). Allele counts in different populations were downloaded from gnomAD (https://gnomad.broadinstitute.org/).

## Table 2

| dbSNP      | Mutation | Binding Affinity Prediction | Mutation Pathogenicity Prediction | Allele Count in Different Populations |
|-----------|----------|-----------------------------|-----------------------------------|--------------------------------------|
| rs73635825 | S19P     | 2.83 0.086 Increasing       | Probably Damaging                 | 63 0 0 0 0                          |
| rs781255386 | T27A    | 3.498 1.004 Increasing     | Tolerated                          | 0 2 0 0 0                          |
| rs1348114695 | E35K    | 2.693 –0.668 Decreasing   | Tolerated                          | 0 0 2 0 1                          |
| rs146667783 | E37K    | 3.314 –1.226 Decreasing   | Probably Damaging                 | 0.163 2.669 2 0 0 6 0              |
| rs769996587 | M82I    | 3.382 –0.521 Decreasing   | Tolerated                          | 0.016 –0.646 5 0 0 0 0 0            |
| rs961360700 | D355N   | 3.547 –0.901 Decreasing   | Tolerated                          | 0.430 3.005 0 0 0 0 0 2             |

The effects of variants on binding affinity were predicted using mcsM-ppi2 (http://biosig.unimelb.edu.au/mcsM_ppi2/). Mutation pathogenicity predictions were extracted from dbNSFP (https://sites.google.com/site/jpopgen/dbNSFP/). Allele counts in different populations were downloaded from gnomAD (https://gnomad.broadinstitute.org/).
of using the target might be better against the spike protein of SARS-CoV-2 than ACE2 because targeting ACE2 per se might impose a detrimental effect on the patient who has the underlying diseases.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

Acknowledgement

This study was supported by an NIH/NIADIC S1CA112785 (Q.T.), National Institute on Minority Health and Health Disparities of the National Institutes of Health under Award Number G12MD007597 and 5U54MD007592. This work was supported by the Howard University startup funds (U100193) and National Science Foundation HDR DSC Award [#1924092].

References

[1] Drexl JP, Gloza-Rausch F, Glende Jo Fehr AR, Perlman S. Coronaviruses: an overview of their replication and evolution. J Virol 2020;84:12:11336–49.

[2] Goldberger AI, Peng CK. Genomic Classification Using an Information-Based Similarity Index: Application to the SARS Coronavirus. J Comput Biol 2005;12(8):1103–16.

[3] Faleur AR, Perlin S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2011;1282:1–23.

[4] Falsey AR, McCann RM, Law H, Vabret A, Lorin V, Escriou N, Giovannetti M, Benvenuto D, Angeletti S, Ciccozzi M. The first two cases of COVID-19 in Italy: Where they came from?. J Med Virol 2020/2/9(5):58–21.

[5] Zhang T, Wu Q, Zhang Z. Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. J Virol 2020;87(7):3445–151.

[6] Li C, Yang Z, Ren L. Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species. Infection, Genet Evol 2020;82:104285. https://doi.org/10.1016/j.meegid.2020.104285.

[7] Xu J, Zhao S, Teng T, Abidalla AE, Zhu W, Xie L, Wang Y, Guo X. 2020. Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses 12.

[8] Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, Liu, He X, Shaai L, Sun Z, Zhao Y, Liu P, Liang C, Wang J, Zhang X, Guan Y, Yan T, Wu G, Chen B, Hu Z. 2020. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-CoV-2. Science doi:10.1126/science.abb7015.

[9] Sanchez S, Lin YT, Xu C, Romero-Severon E, Hengartner N, Ke R. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis 2020;27:1–13.

[10] Hao X, Cheng S, Wu S, Wu T, Lin X, Wang C. Reconstruction of the full transmission dynamics of COVID-19 in Wuhan. Nature 2020. https://doi.org/10.1038/s41588-020-0654-2.

[11] de Angel F, de Angel D, Wang D, Luquez M, Mendez Lazo PA. Weathering the pandemic: How the Caribbean Basin can use viral and environmental patterns to predict, prepare and respond to COVID-19. J Med Virol 2020; https://doi.org/10.1002/jmv.26736.

[12] Gargas, Kim I, Whiskat M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Plu, Chai SJ, Kim L, Whitak
Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pohlmann S. Human renin-angiotensin system blockers and the COVID-19 pandemic: At present there is no evidence to abandon renin-angiotensin system blockers. Lancet Resp Med 2020;8(4):e21. https://doi.org/10.1016/S2213-2600(20)30116-8

Fang L, Karakulakis G, Roth M. Antihypertensive drugs and risk of COVID-19? – Authors’ reply. Lancet Resp Med 2020;8(5):e32–3. https://doi.org/10.1016/S2213-2600(20)30136-0

Fang L, Karakulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Resp Med 2020;8(4):e21. https://doi.org/10.1016/S2213-2600(20)30116-8

Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, Gao H, Liu L, Zhang C. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerging Microbes Infect 2020;9(1):757–70. https://doi.org/10.1038/s41418-020-0319-y

Acanfora D, Ciccone MM, Sicchitano P, Acanfora C, Casucci G. Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients. Eur J Heart Cardiovasc Pharmacother doi:10.1093/ehjcvp/pva028.

Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 2020;81(5):537–60. https://doi.org/10.1002/ddr.21065

Kreutz R, Algharably EAE, Aziiri M, Dobrowolski P, Gukiz T, Januszewicz A, Persu A, Prejzib A, Riemer TG, Wang JG, Burnier M. 2020. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res doi:10.1093/cvr/cvaa137.

Sparks MA, South A, Welling P, Luther JM, Cohen J, Byrd JB, Burrell LM, Batlle D, Cortes C, Hazra S, Murray AG, Vederas JC, Oudit GY. Angiotensin-Converting Enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med 2003;9(12):1579–82. https://doi.org/10.1038/nm1203-1579

Danzel AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID-19 Spike Glycoprotein. Cell 2020;181(2):281–292.e8. https://doi.org/10.1016/j.cell.2020.03.049

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;181(2):271–280.e8.

Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuan K-Y, Wang Q, Zhou H, Yan Y, Qi J. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell 2020;181(4):894–904.e9.

Van R, Zhang Y, Li Y, Xia Lu, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020;367(6485):1444–8. https://doi.org/10.1126/science.abb8452

Qianqian Li JW, Jianhui Nie, Li Zhang, Huan Hao, Shuo Liu, Chenyan Zhao, Qi Zhang, Huan Liu, Lingling Nie, Haitang Qin, Meng Wang, Qiong Liu, Xiaoai Li, Gyu Sun, Junkiu Liu, Linqi Zhang, Xuguang Li, Wenjin Huang, Youshan Chou. 2020. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell in press.

Wang Y, Liu M, Gao J. Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions. Proc Natl Acad Sci USA 2020;117(5):3967–74. https://doi.org/10.1073/pnas.1916387117

Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z, Lu X, Zhang Y, Ma L, Gu W, Xu A, Xu Ji, Shi Z, Ling S, Zou B. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol 2020;17(6):621–30. https://doi.org/10.1038/s41423-020-0352-7

Luo Y, Liu C, Guan T, Li Y, Li L, Li F, Zhao H, Maimaiti T, Zeyawied Y. Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in south China. J Hypertension 2020;38(9):1851–9. https://doi.org/10.1097/HJH.0000000000002620

Ziyun Li, Yang Y, Wang Y, Liu Y, Fu G, Chen D, Dai H, Fan X, Hui R, Zheng H, Yang Z. ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects. Mol Biol Rep 2021;38(9):6581–8. https://doi.org/10.1007/s12050-019-11548-x

Wang W, Jia J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol 2020;92(4):441–7. https://doi.org/10.1002/jmv.25590

Dent T. SARS-CoV-2: Australian experience. Med J Aust 2020;212(9):550–2. https://doi.org/10.5694/mja2.50032

Ocaranza MP, Corvalan AH, Parra V, Lavandero S. 2020. Angiotensin-(1-9) receptor is a functional receptor for SARS coronavirus. Cell Death Differ doi:10.1038/s41418-020-0669-2.

Russell TW, Hellewell J, Jarvis CI, van Zandvoort K, Abbott S, Ratnayake R, Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan D, Sandoval J, Del Valle-Mondragón L, Masso F, Zayas N, Pulido T, Teijeiro R, Bhatia S, Boonyasiri A, Cori A, Cuincubul Z, FitzJohn R, Gaythorpe K, Green W, Hamlet A, Hinley W, Laydon D, Nedjati-Gilani G, Riley S, van Elsland S, Volz E, Wang H, Wang X, Yu X, Donnelly CA, Chani AC, Ferguson NM. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020;20(6):660–77. https://doi.org/10.1016/S1473-3099(20)30083-7

Delgado J, Pankhania B, Majeed A. Protecting older people from COVID-19: should the United Kingdom start at age 60? JR Soc Med 2020. https://doi.org/10.1177/0141076820921107

Russell TW, Hellewell J, Jarvis CI, van Zandvoort K, Abbott S, Ratnayake R, Cmmd-Covid-Working G, Bosch BJ, Haagmans BL. Dipeptidyl peptidase 4 is a functional receptor for Middle East respiratory syndrome coronavirus (MERS-CoV). Virology 2012;427(1):167–73. https://doi.org/10.1016/j.virol.2012.05.014

Lau NL, Yang Y, Wang Y, Liu Y, Fu G, Chen D, Dai H, Fan X, Hui R, Zheng H, Yang Z. ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects. Mol Biol Rep 2021;38(9):6581–8. https://doi.org/10.1007/s12050-019-11548-x

Wang W, Jia J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol 2020;92(4):441–7. https://doi.org/10.1002/jmv.25590

Dent T. SARS-CoV-2: Australian experience. Med J Aust 2020;212(9):550–2. https://doi.org/10.5694/mja2.50032

Ocaranza MP, Corvalan AH, Parra V, Lavandero S. 2020. Angiotensin-(1-9) receptor is a functional receptor for SARS coronavirus. Cell Death Differ doi:10.1038/s41418-020-0669-2.